Article(id=1326652923771203811, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652873431167754, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2025.02.003, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1734364800000, receivedDateStr=2024-12-17, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794228305045, onlineDateStr=2026-11-09, pubDate=1739116800000, pubDateStr=2025-02-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794228305045, onlineIssueDateStr=2026-11-09, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794228305045, creator=13701087609, updateTime=1794228305045, updator=13701087609, issue=Issue{id=1326652873431167754, tenantId=1146029695717560320, journalId=1319690329412173987, year='2025', volume='46', issue='2', pageStart='107', pageEnd='210', issueExtLink='null', onlineDate='null', pubDate='1739116800000', pubDateStr='2025-02-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794228293043, creator='13701087609', updateTime=1794273094848, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1326840786227934185, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652873431167754, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1326840786227934186, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652873431167754, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=130, endPage=137, ext={EN=ArticleExt(id=1326652924077388004, articleId=1326652923771203811, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Clinical progress of glucagon-like peptide-1 receptor agonists in the treatment of metabolically associated steatohepatitis, columnId=1325221107665612978, journalTitle=World Clinical Drug, columnName=Topic, runingTitle=null, highlight=null, articleAbstract=

Metabolic associated steatohepatitis(MASH), formerly known as non-alcoholic steatohepatitis. If the disease is not controlled, it can lead to cirrhosis and liver cancer. With the continuous development of the discipline, the diagnosis and treatment of MASH have made great progress. However, because of its complex mechanism of action, many clinical trials have failed even after entering phase Ⅲ. This aritcle focused on the metabolic disorder of MASH, and summarized the double/triple receptor agonists targeting the metabolism of glucagon peptide-1 receptor and other incretin signaling pathways, so as to provide certain references for the better development of MASH treatment and the design of related clinical trials.

, authors=Yanyan ZENG1, Zhilong LAN2, Yingbo LI2, Shan JIANG2, Na NI1, *, Junlong WANG1, *, authorsList=Yanyan ZENG, Zhilong LAN, Yingbo LI, Shan JIANG, Na NI, Junlong WANG, authorCompany=null, correspAuthors=Na NI, Junlong WANG, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1326652924333240549, articleId=1326652923771203811, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=胰高血糖素样肽-1受体激动剂治疗代谢相关脂肪性肝炎的临床研究进展, columnId=1325221107824996532, journalTitle=世界临床药物, columnName=医药专论, runingTitle=null, highlight=null, articleAbstract=

代谢相关脂肪性肝炎(metabolic associated steatohepatitis,MASH),原名为非酒精性脂肪性肝炎。若不加以控制,其可导致肝硬化及肝癌的发生。随着学科不断发展,MASH的诊断和治疗均有很大进步,但由于其复杂的作用机制,不少临床试验即使进入Ⅲ期也以失败告终。该文从MASH的代谢障碍为考虑点,汇总其靶向代谢的胰高血糖素肽-1受体与其他肠促胰岛素信号通路的双重/三重受体激动剂,为更好地开发MASH治疗及设计相关临床试验提供一定参考。

, authors=曾艳艳1, 兰志龙2, 李英博2, 姜山2, 倪娜1, *, 王俊龙1, *, authorsList=曾艳艳, 兰志龙, 李英博, 姜山, 倪娜, 王俊龙, authorCompany=null, correspAuthors=倪娜, 王俊龙, authorNote=

曾艳艳,硕士研究生,研究方向:临床药学及临床研究。

, correspAuthorsNote=
倪娜,副研究员,研究方向:创新药物的临床研究
王俊龙,副研究员,研究方向:创新药物的临床研究。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=3j1lFEGKBG1v7c2yucH+jw==, magXml=Go2Lh7M97PVIHZWkN3qFUg==, pdfUrl=null, pdf=Ojmiybn4RiNB3cTIOgRUgw==, pdfFileSize=960635, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=GLHPZB2I7b4KgdUMPCTT2A==, mapNumber=null, fund=null)}, authors=[Author(id=1326652924882694382, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652924974969072, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, authorId=1326652924882694382, language=EN, stringName=Yanyan ZENG, firstName=Yanyan, middleName=null, lastName=ZENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652925042077937, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, authorId=1326652924882694382, language=CN, stringName=曾艳艳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国医药工业研究总院临床研究中心,上海 200437, bio={"content":"

曾艳艳,硕士研究生,研究方向:临床药学及临床研究。

"}, bioImg=null, bioContent=

曾艳艳,硕士研究生,研究方向:临床药学及临床研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652924706533607, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, xref=1., ext=[AuthorCompanyExt(id=1326652924735893736, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924706533607, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1326652924744282346, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924706533607, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院临床研究中心,上海 200437)])]), Author(id=1326652925125964019, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652925209850101, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, authorId=1326652925125964019, language=EN, stringName=Zhilong LAN, firstName=Zhilong, middleName=null, lastName=LAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652925327290614, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, authorId=1326652925125964019, language=CN, stringName=兰志龙, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海益临思医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652924811391210, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, xref=2., ext=[AuthorCompanyExt(id=1326652924819779819, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924811391210, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China), AuthorCompanyExt(id=1326652924828168428, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924811391210, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海益临思医药开发有限公司,上海 200437)])]), Author(id=1326652925419565304, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652925537005818, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, authorId=1326652925419565304, language=EN, stringName=Yingbo LI, firstName=Yingbo, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652925591531771, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, authorId=1326652925419565304, language=CN, stringName=李英博, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海益临思医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652924811391210, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, xref=2., ext=[AuthorCompanyExt(id=1326652924819779819, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924811391210, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China), AuthorCompanyExt(id=1326652924828168428, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924811391210, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海益临思医药开发有限公司,上海 200437)])]), Author(id=1326652925662834941, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652925746721023, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, authorId=1326652925662834941, language=EN, stringName=Shan JIANG, firstName=Shan, middleName=null, lastName=JIANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652925818024192, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, authorId=1326652925662834941, language=CN, stringName=姜山, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海益临思医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652924811391210, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, xref=2., ext=[AuthorCompanyExt(id=1326652924819779819, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924811391210, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China), AuthorCompanyExt(id=1326652924828168428, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924811391210, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海益临思医药开发有限公司,上海 200437)])]), Author(id=1326652925872550146, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326652925931270404, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, authorId=1326652925872550146, language=EN, stringName=Na NI, firstName=Na, middleName=null, lastName=NI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652925994184965, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, authorId=1326652925872550146, language=CN, stringName=倪娜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.中国医药工业研究总院临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652924706533607, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, xref=1., ext=[AuthorCompanyExt(id=1326652924735893736, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924706533607, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1326652924744282346, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924706533607, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院临床研究中心,上海 200437)])]), Author(id=1326652926048710919, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, orderNo=5, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326652926111625481, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, authorId=1326652926048710919, language=EN, stringName=Junlong WANG, firstName=Junlong, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652926182928650, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, authorId=1326652926048710919, language=CN, stringName=王俊龙, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.中国医药工业研究总院临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652924706533607, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, xref=1., ext=[AuthorCompanyExt(id=1326652924735893736, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924706533607, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1326652924744282346, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924706533607, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院临床研究中心,上海 200437)])])], keywords=[Keyword(id=1326652926296174859, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, language=EN, orderNo=1, keyword=glucagon-like peptide-1), Keyword(id=1326652926359089420, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, language=EN, orderNo=2, keyword=glucagon-like peptide-1 receptor agonists), Keyword(id=1326652926413615373, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, language=EN, orderNo=3, keyword=metabolic associated steatohepatitis), Keyword(id=1326652926468141326, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, language=EN, orderNo=4, keyword=non-alcoholic steatohepatitis), Keyword(id=1326652926526861583, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, language=EN, orderNo=5, keyword=metabolic associated fatty liver disease), Keyword(id=1326652926585581840, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, language=EN, orderNo=6, keyword=non-alcoholic fatty liver disease), Keyword(id=1326652926648496401, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, language=CN, orderNo=1, keyword=胰高血糖素样肽-1), Keyword(id=1326652926728188178, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, language=CN, orderNo=2, keyword=胰高血糖素样肽-1受体激动剂), Keyword(id=1326652926795297043, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, language=CN, orderNo=3, keyword=代谢相关脂肪性肝炎), Keyword(id=1326652926849822996, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, language=CN, orderNo=4, keyword=非酒精性脂肪性肝炎), Keyword(id=1326652926904348949, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, language=CN, orderNo=5, keyword=代谢相关脂肪性肝病), Keyword(id=1326652926958874902, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, language=CN, orderNo=6, keyword=非酒精性脂肪性肝病)], refs=[Reference(id=1326652927067926807, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=RINELLA ME, LAZARUS JV, RATZIU V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. Ann Hepatol, 2024, 29(1): 101133., articleTitle=null, refAbstract=null), Reference(id=1326652927139229976, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=范建高, 徐小元, 南月敏, 等. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024,27(4): 494-510., articleTitle=null, refAbstract=null), Reference(id=1326652927193755929, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5):947-957., articleTitle=null, refAbstract=null), Reference(id=1326652927252476186, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=MIAO L, TARGHER G, BYRNE CD, et al. Current status and future trends of the global burden of MASLD[J]. Trends Endocrinol Metab, 2024, 35(8): 697-707., articleTitle=null, refAbstract=null), Reference(id=1326652927311196443, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=纪立农, 邹大进, 洪天配, 等. GLP-1受体激动剂临床应用专家指导意见[J]. 中国糖尿病杂志, 2018, 26(5): 353-361., articleTitle=null, refAbstract=null), Reference(id=1326652927369916700, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=NEWSOME PN, BUCHHOLTZ K, CUSI K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis[J]. N Engl J Med, 2021, 384(12): 1113-1124., articleTitle=null, refAbstract=null), Reference(id=1326652927437025565, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=国家药品监督管理局药品审评中心. 重组胰高血糖素样肽-1受体激动剂药学研究与评价技术指导原则(征求意见稿)[EB/OL]. (2024-12-16)[2024-12-16]. https://www.cde.org.cn/main/news/viewInfoCommon/da6047f52aedee4ca9ed09e93517d43b., articleTitle=null, refAbstract=null), Reference(id=1326652927499940126, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209., articleTitle=null, refAbstract=null), Reference(id=1326652927554466079, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=YOUNOSSI ZM, PAIK JM, STEPANOVA M, et al. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease[J]. J Hepatol, 2024, 80(5): 694-701., articleTitle=null, refAbstract=null), Reference(id=1326652927634157856, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=YOUNOSSI ZM, GOLABI P, PAIK JM, et al. The global epidemiology of nonalcoholic fatty liver disease(NAFLD)and nonalcoholic steatohepatitis(NASH): a systematic review[J]. Hepatology, 2023, 77(4): 1335-1347., articleTitle=null, refAbstract=null), Reference(id=1326652927692878113, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=PAIK JM, GOLABI P, YOUNOSSI Y, et al. The growing burden of disability related to nonalcoholic fatty liver disease:data from the global burden of disease 2007—2017[J]. Hepatol Commun, 2020, 4(12):1769-1780., articleTitle=null, refAbstract=null), Reference(id=1326652927785152803, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=HARRISON SA, BEDOSSA P, GUY CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis[J]. N Engl J Med, 2024, 390(6): 497-509., articleTitle=null, refAbstract=null), Reference(id=1326652927864844580, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=XU X, POULSEN KL, WU L, et al. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis(NAFL/NASH)[J]. Signal Transduct Target Ther, 2022, 7(1): 287., articleTitle=null, refAbstract=null), Reference(id=1326652927957119270, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=LEE KC, WU PS, LIN HC. Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis[J]. Clin Mol Hepatol, 2023, 29(1): 77-98., articleTitle=null, refAbstract=null), Reference(id=1326652928032616743, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=YOUNOSSI ZM, GOLABI P, PRICE JK, et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes[J]. Clin Gastroenterol Hepatol, 2024, 22(10): 1999-2010., articleTitle=null, refAbstract=null), Reference(id=1326652928095531304, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=MANTOVANI A, PETRACCA G, BEATRICE G, et al. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals[J]. Gut, 2021, 70(5): 962-969., articleTitle=null, refAbstract=null), Reference(id=1326652928179417385, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHIHONG Y, CHEN W, QIANQIAN Z, et al. Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity[J]. Peptides, 2023,162: 170955., articleTitle=null, refAbstract=null), Reference(id=1326652928280080682, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=叶赛, 鲁一兵. 肠道激素多受体激动剂治疗代谢性疾病的研究进展[J]. 国际内分泌代谢杂志, 2022, 42(6): 477-480., articleTitle=null, refAbstract=null), Reference(id=1326652928355578155, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=LYNGGAARD MB, GASBJERG LS, CHRISTENSEN MB, et al. GIP(3-30)NH2 - a tool for the study of GIP physiology[J]. Curr Opin Pharmacol, 2020, 55: 31-40., articleTitle=null, refAbstract=null), Reference(id=1326652928426881324, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=YABUT JM, DRUCKER DJ. Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease[J]. Endocr Rev, 2023, 44(1): 14-32., articleTitle=null, refAbstract=null), Reference(id=1326652928519156013, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=TARGHER G, MANTOVANI A, BYRNE CD. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease[J]. Lancet Gastroenterol Hepatol, 2023, 8(2): 179-191., articleTitle=null, refAbstract=null), Reference(id=1326652928607236398, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHENG Z, ZONG Y, MA Y, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy[J]. Signal Transduct Target Ther, 2024, 9(1): 234., articleTitle=null, refAbstract=null), Reference(id=1326652928653373743, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=SHANKAR SS, DANIELS SJ, ROBERTSON D, et al. Safety and efficacy of novel incretin Co-agonist cotadutide in biopsy-proven noncirrhotic MASH with fibrosis[J]. Clin Gastroenterol Hepatol, 2024, 22(9): 1847-1857., articleTitle=null, refAbstract=null), Reference(id=1326652928699511088, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=SCHEEN AJ, LEFEBVRE PJ. Glucagon, from past to present: a century of intensive research and controversies[J]. Lancet Diabetes Endocrinol, 2023, 11(2): 129-138., articleTitle=null, refAbstract=null), Reference(id=1326652928766619953, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=PERREAULT L, SKYLER JS, ROSENSTOCK J. Novel therapies with precision mechanisms for type 2 diabetes mellitus[J]. Nat Rev Endocrinol, 2021, 17(6): 364-377., articleTitle=null, refAbstract=null), Reference(id=1326652930461118771, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=KNERR PJ, MOWERY SA, FINAN B, et al. Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates[J]. Peptides, 2020,125: 170225., articleTitle=null, refAbstract=null), Reference(id=1326652930557587765, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=ROMERO-GOMEZ M, LAWITZ E, SHANKAR RR, et al. A phase Ⅱa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease[J]. J Hepatol, 2023, 79(4): 888-897., articleTitle=null, refAbstract=null), Reference(id=1326652930683416886, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=HARRISON SA, BROWNE SK, SUSCHAK JJ, et al. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study[J]. J Hepatol, 2025, 82(1): 7-17., articleTitle=null, refAbstract=null), Reference(id=1326652930767302967, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=WHARTON S, LE ROUX CW, KOSIBOROD MN, et al. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2)[J]. Obesity(Silver Spring), 2025, 33(1): 67-77., articleTitle=null, refAbstract=null), Reference(id=1326652930830217528, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=SANYAL AJ, BEDOSSA P, FRAESSDORF M, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis[J].N Engl J Med, 2024, 391(4): 311-319., articleTitle=null, refAbstract=null), Reference(id=1326652930897326393, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=LE ROUX CW, STEEN O, LUCAS KJ, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial[J]. Lancet Diabetes Endocrinol, 2024, 12(3):162-173., articleTitle=null, refAbstract=null), Reference(id=1326652930981212474, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=WADDEN TA, CHAO AM, MACHINENI S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial[J]. Nat Med, 2023, 29(11): 2909-2918., articleTitle=null, refAbstract=null), Reference(id=1326652931052515643, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=LOOMBA R, HARTMAN ML, LAWITZ EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis[J]. N Engl J Med, 2024,391(4): 299-310., articleTitle=null, refAbstract=null), Reference(id=1326652931132207420, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=国家药品监督管理总局. 非酒精性脂肪性肝炎治疗药物临床试验指导原则(试行)[EB/OL]. (2019-12-17)[2019-12-30]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20191220141201879.html., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1326652924706533607, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, xref=1., ext=[AuthorCompanyExt(id=1326652924735893736, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924706533607, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1326652924744282346, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924706533607, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院临床研究中心,上海 200437)]), AuthorCompany(id=1326652924811391210, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, xref=2., ext=[AuthorCompanyExt(id=1326652924819779819, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924811391210, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China), AuthorCompanyExt(id=1326652924828168428, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924811391210, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海益临思医药开发有限公司,上海 200437)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.02.003, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.02.003, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2025.02.003, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2025.02.003, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1739116800000, fullTextJson=null, articleText=null, reference=null)
收藏切换
胰高血糖素样肽-1受体激动剂治疗代谢相关脂肪性肝炎的临床研究进展
曾艳艳 1 , 兰志龙 2 , 李英博 2 , 姜山 2 , 倪娜 1, * , 王俊龙 1, *
世界临床药物 | 医药专论 2025,46(2): 130-137
收起
收藏切换
世界临床药物 |医药专论 2025 , 46 (2) : 130 -137
胰高血糖素样肽-1受体激动剂治疗代谢相关脂肪性肝炎的临床研究进展
全屏
[Author(id=1326652924882694382, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652924974969072, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, authorId=1326652924882694382, language=EN, stringName=Yanyan ZENG, firstName=Yanyan, middleName=null, lastName=ZENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652925042077937, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, authorId=1326652924882694382, language=CN, stringName=曾艳艳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国医药工业研究总院临床研究中心,上海 200437, bio={"content":"

曾艳艳,硕士研究生,研究方向:临床药学及临床研究。

"}, bioImg=null, bioContent=

曾艳艳,硕士研究生,研究方向:临床药学及临床研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652924706533607, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, xref=1., ext=[AuthorCompanyExt(id=1326652924735893736, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924706533607, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1326652924744282346, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924706533607, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院临床研究中心,上海 200437)])]), Author(id=1326652925125964019, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652925209850101, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, authorId=1326652925125964019, language=EN, stringName=Zhilong LAN, firstName=Zhilong, middleName=null, lastName=LAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652925327290614, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, authorId=1326652925125964019, language=CN, stringName=兰志龙, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海益临思医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652924811391210, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, xref=2., ext=[AuthorCompanyExt(id=1326652924819779819, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924811391210, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China), AuthorCompanyExt(id=1326652924828168428, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924811391210, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海益临思医药开发有限公司,上海 200437)])]), Author(id=1326652925419565304, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652925537005818, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, authorId=1326652925419565304, language=EN, stringName=Yingbo LI, firstName=Yingbo, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652925591531771, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, authorId=1326652925419565304, language=CN, stringName=李英博, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海益临思医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652924811391210, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, xref=2., ext=[AuthorCompanyExt(id=1326652924819779819, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924811391210, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China), AuthorCompanyExt(id=1326652924828168428, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924811391210, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海益临思医药开发有限公司,上海 200437)])]), Author(id=1326652925662834941, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652925746721023, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, authorId=1326652925662834941, language=EN, stringName=Shan JIANG, firstName=Shan, middleName=null, lastName=JIANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652925818024192, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, authorId=1326652925662834941, language=CN, stringName=姜山, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海益临思医药开发有限公司,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652924811391210, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, xref=2., ext=[AuthorCompanyExt(id=1326652924819779819, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924811391210, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China), AuthorCompanyExt(id=1326652924828168428, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924811391210, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海益临思医药开发有限公司,上海 200437)])]), Author(id=1326652925872550146, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326652925931270404, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, authorId=1326652925872550146, language=EN, stringName=Na NI, firstName=Na, middleName=null, lastName=NI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652925994184965, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, authorId=1326652925872550146, language=CN, stringName=倪娜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.中国医药工业研究总院临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652924706533607, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, xref=1., ext=[AuthorCompanyExt(id=1326652924735893736, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924706533607, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1326652924744282346, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924706533607, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院临床研究中心,上海 200437)])]), Author(id=1326652926048710919, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, orderNo=5, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326652926111625481, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, authorId=1326652926048710919, language=EN, stringName=Junlong WANG, firstName=Junlong, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652926182928650, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, authorId=1326652926048710919, language=CN, stringName=王俊龙, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.中国医药工业研究总院临床研究中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652924706533607, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, xref=1., ext=[AuthorCompanyExt(id=1326652924735893736, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924706533607, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1326652924744282346, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652923771203811, companyId=1326652924706533607, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院临床研究中心,上海 200437)])])]
曾艳艳1, 兰志龙2, 李英博2, 姜山2, 倪娜1, *, 王俊龙1, *
作者信息
  • 1.中国医药工业研究总院临床研究中心,上海 200437
  • 2.上海益临思医药开发有限公司,上海 200437
通讯作者:
倪娜,副研究员,研究方向:创新药物的临床研究
王俊龙,副研究员,研究方向:创新药物的临床研究。
作者简介:

曾艳艳,硕士研究生,研究方向:临床药学及临床研究。

Clinical progress of glucagon-like peptide-1 receptor agonists in the treatment of metabolically associated steatohepatitis
Yanyan ZENG1, Zhilong LAN2, Yingbo LI2, Shan JIANG2, Na NI1, *, Junlong WANG1, *
Affiliations
  • 1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China
  • 2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China
出版时间: 2025-02-10 doi: 10.13683/j.wph.2025.02.003
文章导航
收藏切换

代谢相关脂肪性肝炎(metabolic associated steatohepatitis,MASH),原名为非酒精性脂肪性肝炎。若不加以控制,其可导致肝硬化及肝癌的发生。随着学科不断发展,MASH的诊断和治疗均有很大进步,但由于其复杂的作用机制,不少临床试验即使进入Ⅲ期也以失败告终。该文从MASH的代谢障碍为考虑点,汇总其靶向代谢的胰高血糖素肽-1受体与其他肠促胰岛素信号通路的双重/三重受体激动剂,为更好地开发MASH治疗及设计相关临床试验提供一定参考。

胰高血糖素样肽-1  /  胰高血糖素样肽-1受体激动剂  /  代谢相关脂肪性肝炎  /  非酒精性脂肪性肝炎  /  代谢相关脂肪性肝病  /  非酒精性脂肪性肝病

Metabolic associated steatohepatitis(MASH), formerly known as non-alcoholic steatohepatitis. If the disease is not controlled, it can lead to cirrhosis and liver cancer. With the continuous development of the discipline, the diagnosis and treatment of MASH have made great progress. However, because of its complex mechanism of action, many clinical trials have failed even after entering phase Ⅲ. This aritcle focused on the metabolic disorder of MASH, and summarized the double/triple receptor agonists targeting the metabolism of glucagon peptide-1 receptor and other incretin signaling pathways, so as to provide certain references for the better development of MASH treatment and the design of related clinical trials.

glucagon-like peptide-1  /  glucagon-like peptide-1 receptor agonists  /  metabolic associated steatohepatitis  /  non-alcoholic steatohepatitis  /  metabolic associated fatty liver disease  /  non-alcoholic fatty liver disease
曾艳艳, 兰志龙, 李英博, 姜山, 倪娜, 王俊龙. 胰高血糖素样肽-1受体激动剂治疗代谢相关脂肪性肝炎的临床研究进展. 世界临床药物, 2025 , 46 (2) : 130 -137 . DOI: 10.13683/j.wph.2025.02.003
Yanyan ZENG, Zhilong LAN, Yingbo LI, Shan JIANG, Na NI, Junlong WANG. Clinical progress of glucagon-like peptide-1 receptor agonists in the treatment of metabolically associated steatohepatitis[J]. World Clinical Drug, 2025 , 46 (2) : 130 -137 . DOI: 10.13683/j.wph.2025.02.003

参考文献 引证文献
排序方式:
[1]
RINELLA ME, LAZARUS JV, RATZIU V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. Ann Hepatol, 2024, 29(1): 101133.
[2]
范建高, 徐小元, 南月敏, 等. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024,27(4): 494-510.
[3]
中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5):947-957.
[4]
MIAO L, TARGHER G, BYRNE CD, et al. Current status and future trends of the global burden of MASLD[J]. Trends Endocrinol Metab, 2024, 35(8): 697-707.
[5]
纪立农, 邹大进, 洪天配, 等. GLP-1受体激动剂临床应用专家指导意见[J]. 中国糖尿病杂志, 2018, 26(5): 353-361.
[6]
NEWSOME PN, BUCHHOLTZ K, CUSI K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis[J]. N Engl J Med, 2021, 384(12): 1113-1124.
[7]
国家药品监督管理局药品审评中心. 重组胰高血糖素样肽-1受体激动剂药学研究与评价技术指导原则(征求意见稿)[EB/OL]. (2024-12-16)[2024-12-16]. https://www.cde.org.cn/main/news/viewInfoCommon/da6047f52aedee4ca9ed09e93517d43b.
[8]
ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209.
[9]
YOUNOSSI ZM, PAIK JM, STEPANOVA M, et al. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease[J]. J Hepatol, 2024, 80(5): 694-701.
[10]
YOUNOSSI ZM, GOLABI P, PAIK JM, et al. The global epidemiology of nonalcoholic fatty liver disease(NAFLD)and nonalcoholic steatohepatitis(NASH): a systematic review[J]. Hepatology, 2023, 77(4): 1335-1347.
[11]
PAIK JM, GOLABI P, YOUNOSSI Y, et al. The growing burden of disability related to nonalcoholic fatty liver disease:data from the global burden of disease 2007—2017[J]. Hepatol Commun, 2020, 4(12):1769-1780.
[12]
HARRISON SA, BEDOSSA P, GUY CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis[J]. N Engl J Med, 2024, 390(6): 497-509.
[13]
XU X, POULSEN KL, WU L, et al. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis(NAFL/NASH)[J]. Signal Transduct Target Ther, 2022, 7(1): 287.
[14]
LEE KC, WU PS, LIN HC. Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis[J]. Clin Mol Hepatol, 2023, 29(1): 77-98.
[15]
YOUNOSSI ZM, GOLABI P, PRICE JK, et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes[J]. Clin Gastroenterol Hepatol, 2024, 22(10): 1999-2010.
[16]
MANTOVANI A, PETRACCA G, BEATRICE G, et al. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals[J]. Gut, 2021, 70(5): 962-969.
[17]
ZHIHONG Y, CHEN W, QIANQIAN Z, et al. Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity[J]. Peptides, 2023,162: 170955.
[18]
叶赛, 鲁一兵. 肠道激素多受体激动剂治疗代谢性疾病的研究进展[J]. 国际内分泌代谢杂志, 2022, 42(6): 477-480.
[19]
LYNGGAARD MB, GASBJERG LS, CHRISTENSEN MB, et al. GIP(3-30)NH2 - a tool for the study of GIP physiology[J]. Curr Opin Pharmacol, 2020, 55: 31-40.
[20]
YABUT JM, DRUCKER DJ. Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease[J]. Endocr Rev, 2023, 44(1): 14-32.
[21]
TARGHER G, MANTOVANI A, BYRNE CD. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease[J]. Lancet Gastroenterol Hepatol, 2023, 8(2): 179-191.
[22]
ZHENG Z, ZONG Y, MA Y, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy[J]. Signal Transduct Target Ther, 2024, 9(1): 234.
[23]
SHANKAR SS, DANIELS SJ, ROBERTSON D, et al. Safety and efficacy of novel incretin Co-agonist cotadutide in biopsy-proven noncirrhotic MASH with fibrosis[J]. Clin Gastroenterol Hepatol, 2024, 22(9): 1847-1857.
[24]
SCHEEN AJ, LEFEBVRE PJ. Glucagon, from past to present: a century of intensive research and controversies[J]. Lancet Diabetes Endocrinol, 2023, 11(2): 129-138.
[25]
PERREAULT L, SKYLER JS, ROSENSTOCK J. Novel therapies with precision mechanisms for type 2 diabetes mellitus[J]. Nat Rev Endocrinol, 2021, 17(6): 364-377.
[26]
KNERR PJ, MOWERY SA, FINAN B, et al. Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates[J]. Peptides, 2020,125: 170225.
[27]
ROMERO-GOMEZ M, LAWITZ E, SHANKAR RR, et al. A phase Ⅱa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease[J]. J Hepatol, 2023, 79(4): 888-897.
[28]
HARRISON SA, BROWNE SK, SUSCHAK JJ, et al. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study[J]. J Hepatol, 2025, 82(1): 7-17.
[29]
WHARTON S, LE ROUX CW, KOSIBOROD MN, et al. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2)[J]. Obesity(Silver Spring), 2025, 33(1): 67-77.
[30]
SANYAL AJ, BEDOSSA P, FRAESSDORF M, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis[J].N Engl J Med, 2024, 391(4): 311-319.
[31]
LE ROUX CW, STEEN O, LUCAS KJ, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial[J]. Lancet Diabetes Endocrinol, 2024, 12(3):162-173.
[32]
WADDEN TA, CHAO AM, MACHINENI S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial[J]. Nat Med, 2023, 29(11): 2909-2918.
[33]
LOOMBA R, HARTMAN ML, LAWITZ EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis[J]. N Engl J Med, 2024,391(4): 299-310.
[34]
国家药品监督管理总局. 非酒精性脂肪性肝炎治疗药物临床试验指导原则(试行)[EB/OL]. (2019-12-17)[2019-12-30]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20191220141201879.html.
2025年第46卷第2期
57
12
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2025.02.003
  • 接收时间:2024-12-17
  • 首发时间:2026-11-09
  • 出版时间:2025-02-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2024-12-17
基金
作者信息
    1.中国医药工业研究总院临床研究中心,上海 200437
    2.上海益临思医药开发有限公司,上海 200437

通讯作者:

倪娜,副研究员,研究方向:创新药物的临床研究
王俊龙,副研究员,研究方向:创新药物的临床研究。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.02.003
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏